New Imaging Technology to Assess Effect of Enzyme Replacment Therapy on Eye Disease Progession in Mucopolysacchardiosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02583152|
Recruitment Status : Recruiting
First Posted : October 22, 2015
Last Update Posted : November 28, 2017
|Condition or disease|
The mucopolysaccharidoses (MPS) are a group of hereditary disorders which arise from defects in enzymes which break down glycosaminoglycans (GAGs) which occur in a wide variety of tissues, resulting in multiple systemic complications. Sight loss occurs in MPS due to corneal clouding, retinal degeneration, glaucoma and damage to the optic nerve. Corneal opacification occurs in infancy in several MPS subtypes and in the untreated disease the opacification is thought to be progressive, contributing to significant visual impairment in many patients. Improvements in quality of life and lifespan as a result of early treatment (with enzyme replacement therapy and haematopoetic stem cell transplantation) have meant that management of ocular complications and preservation of vision has increased importance.
A repeatable, reliable technique for quantification of corneal clouding will allow objective demonstration of the effect of treatments such as ERT in stabilisation or improvement of corneal clouding, and to establish the natural history of corneal opacification in MPS.
The investigators have previously developed the Iris camera (Irisguard Corp, McLean, VA 22102, USA) technology to give an objective measure of corneal clouding (Irisguard model IGAD100 ®) (Aslam et al 2009). The investigators demonstrated that use of the iris camera for corneal opacification assessment in MPS is feasibile, practical and has shown evidence for validity and reliability (Aslam et al 2012) (research funded in part by Biomarin Europe Ltd). The densitometry program for the Pentacam® Scheimpflug camera has also been shown to be able to provide measurements of corneal clouding in MPS .This research proposal will allow us to use to these techniques to quantify corneal clouding over time in MPS patients and to assess the effects of treatment with ERT and HSCT on corneal opacification.
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Official Title:||Use of New Imaging Technology to Assess Effect of Enzyme Replacment Therapy on Eye Disease Progession in Mucopolysacchardiosis|
|Study Start Date :||November 2015|
|Estimated Primary Completion Date :||November 2020|
|Estimated Study Completion Date :||November 2020|
MPS patient cohort
Participants with Mucopolysaccharidosis. types I-IV, VI and VII will be recruited from the paediatric and adult ophthalmology. Participants over the age of three who are able to comply and be investigated.
- Corneal densitometry scores in participants on treatment [ Time Frame: 60 months study period ]
- Corneal clouding score over time in patients on treatment. [ Time Frame: 60 months study period ]
- Repeatability and accessibility for each imaging technique [ Time Frame: 60 months study period ]
- Retinal morphology changes with Optos wide field digital imaging and high resolution OCT [ Time Frame: 60 months study period ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02583152
|Contact: Jane Ashworth, MBChB||Jane.Ashworth@cmft.nhs.uk|
|Manchester Royal Eye Hospital||Recruiting|
|Manchester, United Kingdom, M13 9WL|
|Contact: Jane Ashworth email@example.com|
|Contact: Monika Cien 01617011765 firstname.lastname@example.org|
|Principal Investigator:||Jane Ashworth, MBChB, PhD||Central Manchester Foundation Trust|